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ABSTRACT
Background. The separate value of endoscopic ultraso-
nography (EUS), multidetector computed tomography
(CT), and 18F-fluorodeoxyglucose positron emission
tomography (FDG-PET) in the optimal sequence in staging
esophageal cancer has not been investigated adequately.
Methods. The staging records of 216 consecutive oper-
able patients with esophageal cancer were reviewed
blindly. Different staging strategies were analyzed, and the
likelihood ratio (LR) of each module was calculated con-
ditionally on individual patient characteristics. A logistic
regression approach was used to determine the most
favorable staging strategy.
Results. Initial EUS results were not significantly related
to the LRs of initial CT and FDG-PET results. The positive
LR (LR?) of EUS-fine-needle aspiration (FNA) was 4,
irrespective of CT and FDG-PET outcomes. The LR? of
FDG-PET varied from 13 (negative CT) to 6 (positive CT).
The LR? of CT ranged from 3–4 (negative FDG-PET) to
2–3 (positive FDG-PET). Age, histology, and tumor length
had no significant impact on the LRs of the three diagnostic
tests.
Conclusions. This study argues in favor of PET/CT rather
than EUS as a predictor of curative resectability in
esophageal cancer. EUS does not correspond with either
CT or FDG-PET. LRs of FDG-PET were substantially
different between subgroups of negative and positive CT
results and vice versa.
Accurate preoperative staging in esophageal cancer is
important in the choice of treatment, preventing unneces-
sary toxic preoperative chemoradiation and/or surgical
explorations. Moreover, it is essential to determine optimal
treatment and to monitor treatment response after neoad-
juvant therapy.1–3 Radical surgery with curative intent is
only possible if distant metastases (M1) and infiltration of
the primary tumor into adjacent vital structures (T4b) are
absent. If present, primary (chemo)radiation, brachyther-
apy or stent placement are more adequate and less invasive
alternatives as palliative treatment.4–7
Currently, preoperative staging of esophageal cancer
includes endoscopic ultrasonography (EUS) with or with-
out fine-needle aspiration (FNA) of suspicious lymph
nodes, 16–64 multidetector/slice computed tomography
(CT), external ultrasound (US) of the cervical region, and
bronchoscopic examination, if indicated, in mid/upper
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thoracic tumors. To detect distant nodal and systemic
metastases, whole-body positron emission tomography
with 18F-fluordeoxyglucose (FDG-PET) or PET/CT is
widely used.3 These staging methods are used in different
sequences, according to the guidelines employed. Despite
these dedicated staging techniques, surgical resection is
still abandoned in 10–50% of all cases due to excessive
locoregional tumor extent or presence of distant
metastases.3,8
Assessment of resectability is based on both local and
distant criteria. Imaging techniques are more or less com-
plementary, but outcome may also depend on the sequence
of the preoperative workup. Furthermore, a recent study
showed significant but small differences in perceived
patient burden between PET and CT compared with EUS.9
Therefore, it is important to know the adequate sequences
of these different diagnostic methods and when to use
PET/CT or only CT (upfront), followed by EUS, and vice
versa. Several studies found that FDG-PET combined with
EUS-FNA improved preoperative staging of esophageal
cancer.3,10–13 Fusion of FDG-PET and CT images also
provided an increase in preoperative management from 6 to
25%.14–16 The optimal staging strategy, however, remains
unclear, and the additional value of combined PET/CT has
not been determined adequately yet.
Therefore, we used a logistic regression approach to
determine the extent to which the individual value of each
diagnostic staging technique depends on the order in which
the procedure is applied and to determine if this staging
method adds useful information to what is already known,
either because of individual characteristics or on the basis
of preliminary staging results.17 Three routine diagnostic
staging techniques (EUS, CT, and FDG-PET) were tested
in terms of curatively intended resectability of esophageal
cancer. For this purpose, we compared the likelihood ratios
(LRs) in different staging strategies, calculated at the level
of the individual patient.
PATIENTS AND METHODS
Study Design
The medical records from a multicenter (Academic
Medical Center, Amsterdam and University Medical Cen-
ter, Groningen) prospective cohort staging improvement
study lasting from October 2002 to October 2004 were
used.18 The study consisted of 258 consecutive patients
with biopsy-proven cancer of the thoracic esophagus or
gastroesophageal junction (GEJ). Exclusion criteria were
age \18 years, inability to undergo major surgery, preg-
nancy, and history of another malignancy in the previous
5 years. According to the above-mentioned criteria, 216
operable patients were eligible for participation. Informed
consent was obtained from all 216 patients who formed our
study population. Patient and tumor characteristics are
listed in Table 1. All these patients underwent thoracic and
abdominal CT, EUS with FNA on indication, and whole-
body FDG-PET within a time period of 6 weeks. All PET/
CT and EUS were performed and reviewed independently
by well-trained and experienced investigators in both
highly qualified centers. Interpretation of each modality
was blinded, and investigators were unaware of other
clinical or diagnostic data.18 Resectability was determined
by local tumor invasion of vital structures, excluding non-
curatively resectable group of unresectable tumor (T4b),
unresectable conglomerate of nonregional nodal disease, or
distant metastases (M1). Distant metastases included
lymph node metastases in the cervical area or at the celiac
axis depending upon primary tumor location or hematog-
enous metastases, usually to liver and lungs and bone
metastasis. To exclude pathological cervical lymph nodes,
external ultrasonography of the neck with FNA was per-
formed on indication. All potential sites of incurable
disease were confirmed pathologically or were followed
with additional imaging during at least 12 months. All
records, including histology achieved from biopsy, surgical
explorations, and resections were registered and available
for analysis. Pathological confirmation or any progression
of unconfirmed suspicious lesion during 6-month follow-up
was considered as gold standard.
Computed Tomography
A 16 or 64 multidetector row spiral CT scanner (Philips
MX 8000; Philips Medical Systems, Best, The Netherlands
or Somatom Sensation; Siemens Medical Systems, Erlan-
gen, Germany) was used for CT imaging. CT scans
(collimation 16 9 1.5 mm) were performed with both
intravenous and oral contrast fluid and achieved in cra-
niocaudal direction from the neck to the upper abdomen
including the liver. Images had 3 mm reconstructed slice
thickness with 1.5 mm effective section thickness. Round
lymph nodes with low attenuation and lymph nodes with a
size cutoff of 10 mm in smallest diameter were suspected
to be pathologic.
Endoscopic Ultrasound
EUS was performed with a radial scanner (GF-UM 130
or GF-UM160, 5–20 MHz; Olympus Medical Systems,
Tokyo, Japan), and EUS-guided FNA of suspected lymph
nodes was obtained via a separate linear-array echoendo-
scope (GIF-UC140P; Olympus Medical Systems, Tokyo,
Japan or FGUX-36, 5–7.5 MHz; Pentax, Benelux, Breda,
The Netherlands). A 22-gauge needle was used for
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aspiration (Echo tip; Wilson-Cook Medical Inc., Winston-
Salem, NC). If passage of a standard echoendoscope was
not feasible because of stenosis, a small-caliber probe
(MH-908, 7.5 MHz; Olympus Medical Systems, Tokyo,
Japan) was used in an attempt to pass the tumor. EUS was
performed with the patient in left decubitus position under
sedation using 2.5–10 mg midazolam intravenously.
Positron Emission Tomography with 18F-
Fluorodeoxyglucose
All patients were fasted for at least 4 h before FDG-PET
imaging. FDG-PET was performed with an ECAT 951/31
or an ECAT HR? positron camera (Siemens/CTI, Knox-
ville, TN, USA). Depending on body weight, a mean dose
of 400–580 MBq FDG was administered intravenously.
Data acquisition started in whole-body mode 90 min after
injection, for 5 min per bed position from the skull to the
mid femur.
Statistical Analyses
The results of EUS, CT, and FDG-PET together with the
results of surgical exploration and pathological evaluation
of the resection specimen were converted into a final gold-
standard dichotomous outcome: resectable with curative
intent (‘‘resectable’’ hereinafter), or incurable/unresectable.
Baseline variables were divided into three groups: (1)
individual patient characteristics including age and gender,
(2) tumor characteristics of the primary tumor including
histological type, location, and length measured on EUS,
and (3) staging characteristics including EUS outcome, CT
outcome, and FDG-PET outcome. Resectable and unre-
sectable tumors were compared by using the Pearson
TABLE 1 Clinicopathological characteristics and univariate analysis of coefficients
N = 216 % Resectable (n = 150) Unresectable (n = 66) p-Value
Gender 0.60
Male 181 83.8 84.7% 81.8%
Female 35 16.2
Age (years) 0.11
Median (range) 63 29–82 63.44 (9.26) 61.17 (10.05)
Localizationa 0.14
High 23 10.6 12 (8.0%) 11 (16.7%)
Low 139 64.4 101 (67.3%) 38 (57.6%)
GEJ 54 25.0 37 (24.7%) 17 (25.8%)
Tumor length (cm) 0.001
Median (range) 5.0 0–18 5.47 7.36
Histological type 0.058
AC 168 77.8 122 (81.3%) 46 (69.7%)
SCC 48 22.2 28 (18.7%) 20 (30.3%)
Test outcomes
EUS outcome Unresectable 2 (1.3%) 8 (12.1%) n.a.
CT outcome Unresectable 9 (6.0%) 26 (39.4%) n.a.
FDG-PET outcome Unresectable 5 (3.3%) 30 (45.5) n.a.
Clinical stage
T1 9 4.2
T2 22 10.4
T3 171 80.7
T4 10 4.7
Missing value 4 –
Staging based on total staging (EUS-FNA, CT, FDG-PET, and additional investigations, such as external sonography of the neck and
bronchoscopy)
GEJ gastroesophageal junction, tumor length length of the tumor on EUS, AC adenocarcinoma, SCC squamous cell carcinoma, MWU Mann–
Whitney U-test, v2 Pearson chi-square test, grouping variable: irresectability
a High, above the carina, Low, below the carina
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chi-square test (v2) for ordinal/nominal variables and the
Mann–Whitney U-test (MWU) for continuous variables.
To estimate the probability of curative surgery (resect-
able) versus palliative treatment (unresectable), logistic
regression analyses were used according to a recently
developed regression approach.17 In this approach, the
regression equation for the likelihood ratio (LR) of the test
results (logistic regression model) is obtained by taking the
difference in coefficients between prior and posterior odds.
The prior odds model included all covariates that were
significantly related to the resectability of the esophageal
malignancy. The posterior odds model included all vari-
ables from the prior odds model plus the results of one or
two of the additional imaging tests. In this way, the LR of a
resectable tumor is calculated for individual risk profiles. In
the conventional log-odds formulation of the Bayes rule,
the natural logarithm (ln) of LR is the difference between
ln(posterior odds) and ln(prior odds).17,19 Although we
performed regression analyses for the three diagnostic
imaging modalities in various sequences, only the four
scenarios which are clinically relevant are presented (sce-
narios A–D, Fig. 1).
Descriptive statistics were obtained using SPSS 14.0 for
Windows. The multivariable logistic regression analyses
for prior and posterior odds models and the LR were pro-
grammed in S-PLUS (V6; Insightful Corp., Seattle, WA).
Values of p less than 0.05 were considered statistically
significant.
RESULTS
The length of the tumor was a statistically significant
risk factor for irresectability (p = 0.001). Not surprisingly,
all staging characteristics were also significantly related
with curative resectability. Age, gender, tumor location,
and histological type were not significantly correlated with
curative resection (Table 1). For each scenario (Fig. 1,
models A–D), the coefficients of the ln(prior odds),
ln(posterior odds), and ln(LR) regression models are pre-
sented in Table 2. Age, histological type, and tumor length
did not significantly contribute to the LRs of the involved
diagnostic tests in any of the models (p [ 0.05).
Impact of Different Staging Tests in Different Staging
Scenarios
Figure 2 illustrates the difference a test outcome
(Fig. 2a–c) and histological type (Fig. 2d) made on the
LR? of a following test. We chose tumor length as the
X-variable only to spread out our dot plot rather than
because of its correlation with the outcomes of the inves-
tigated modalities. In Fig. 2a, b, there is a significant
difference between negative and positive outcomes of the
preceding test. In Fig. 2c, the effect of EUS after PET or
CT is not significant, although there is a tendency towards
a visually apparent clustering into four groups. This is
based on the combination of positive/negative CT results
and histological type (adenocarcinoma/squamous cell car-
cinoma; Fig. 2d).
In Table 2, the outcomes of EUS were not significantly
related with either the LRs of the CT results or with the
LRs of the FDG-PET results (model A; p = 0.49 and
p = 0.91, respectively). CT results were strongly related to
the LRs of the FDG-PET results (Table 2, model A;
p = 0.03). The negative regression coefficient for CT
(Table 2, model D; coeff. = -0.73) indicates that LR?
and LR- of FDG-PET were lower when CT was also
positive compared with negative CT findings. Visa versa,
FDG-PET results were strongly related with the LRs of CT
(Table 2, model C; p = 0.01). EUS had no impact as a test
for incurability, if it was performed after FDG-PET and CT
in the staging workup (Table 2, model C; p = 0.57), nor
was there a significant relation between FDG-PET ? CT
results and the LRs of EUS (Table 2, model C; p = 0.92
and p = 0.45, respectively). There was also no significant
relation between FDG-PET imaging and the LRs of EUS-
FNA (Table 2, model B; p = 0.95). However, in the
workup with FDG-PET and EUS-FNA, PET was strongly
related to the LRs of CT imaging, but EUS-FNA was not
(Table 2, model B; p = 0.02 and p = 0.50, respectively).
Optimal Preoperative Workup
In Fig. 1 it is already obvious that a staging scenario
with a PET scan upfront followed by CT and EUS will
yield the highest ratio of true-negative test outcomes of all
one- and two-step strategies.
According to all of the above-described models, we
composed an idealized protocol for optimal staging workup
using EUS, CT, and FDG-PET on split levels for patients
EU S + +CT
One method: first staging procedure
Second method: two staging procedures
Third method: three staging procedures
Percentage true negatives = correctly selected patients for surgery
PET
71%
PE T + +EU S CT
80%79% 84% → →
PE T + +CT EUS
80%
%
→ →
CT + +EU S PET
78% → →
→ → 82% 84%
83% 84% 79% 84%
a b
c d
FIG. 1 Models A–D: Four different staging scenarios and the number
of true-negative test outcomes of each one-, two-, and three-step
procedure (in percentages)
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with clearly resectable, questionably resectable, and irre-
sectable esophageal tumors (Fig. 3). In this flowchart, we
recommend performance of PET/CT upfront in every
patient, followed by EUS in those with clearly resectable
disease to identify patients with locally advanced disease,
as they may benefit from neoadjuvant chemoradiation
before surgery. When there is disagreement about resect-
ability with curative intent based on the location of suspect
lymph nodes or because of tumor depth, we advise EUS-
FNA for pathological examination of FDG-avid sites and/
or suspicious lesions on PET/CT imaging in advanced,
questionably resectable disease. In patients with primary
irresectable disease that could possibly be managed cura-
tively by definitive chemoradiation, EUS-FNA should be
performed on indication. However, EUS can be omitted in
patients with clearly incurable disease, so they can be
referred immediately for palliative treatment.
DISCUSSION
In this study a validated reformulated logistic regression
approach was used to calculate the likelihood ratios of CT,
FDG-PET, and EUS in order to determine the resectability
with curative intent for different patient, tumor, and staging
characteristics.17 Given the outcomes of one or two diag-
nostic tests, we were able to determine the value added by
each test in the staging workup of esophageal cancer
patients in predicting a dichotomous outcome (curative
resectability versus irresectability). It was not possible to
make subdivisions based on age, histological type, or
tumor length in deciding whether to perform a test or not.
According to the results of this logistic regression
approach, PET/CT has to be recommended as the first
staging procedure, reserving EUS for limited cases and
candidates with curable disease (Fig. 3). CT and FDG-PET
TABLE 2 Logistic regression models for the likelihood ratio of CT, FDG-PET, and EUS conditional on age, tumor length, and histological type
Stage Test Covariate Logistic regression Likelihood ratio
Coeff. SE p-Value Coeff. SE p-Value
Order A: 1. EUS, 2. CT, 3. FDG-PET
I EUS – 1.79 0.86 0.04 – – –
II EUS 1.42 0.97 0.14 -0.37 0.53 0.49
CT 2.42 0.46 \0.001 2.42 0.60 \0.001
III EUS 1.48 1.01 0.14 0.06 0.53 0.91
CT 1.69 0.53 0.001 -0.73 0.33 0.03
FDG-PET 2.91 0.57 \0.001 2.91 0.92 0.001
Order B: 1. FDG-PET, 2. EUS, 3. CT
I FDG-PET – 3.37 0.55 \0.001 – – –
II FDG-PET 3.36 0.55 \0.001 -0.01 0.07 0.95
EUS 1.81 0.93 0.05 1.81 2.73 0.51
III FDG-PET 2.91 0.57 \0.001 -0.45 0.19 0.02
EUS 1.48 1.01 0.14 -0.33 0.49 0.50
CT 1.69 0.53 0.001 1.69 0.65 0.01
Order C: 1. FDG-PET, 2. CT, 3. EUS
I FDG-PET – 3.37 0.55 \0.001 – – –
II FDG-PET 2.90 0.57 \0.001 -0.46 0.19 0.01
CT 1.78 0.52 0.001 1.78 0.54 0.001
III FDG-PET 2.91 0.57 \0.001 0.01 0.10 0.92
CT 1.69 0.53 0.001 -0.08 0.11 0.45
EUS 1.48 1.01 0.14 1.48 2.62 0.57
Order D: 1. CT, 2. EUS, 3. FDG-PET
I CT – 2.47 0.45 \0.001 – – –
II CT 2.42 0.46 \0.001 0.05 0.06 0.44
EUS 1.42 0.97 0.14 1.42 2.61 0.59
III CT 1.69 0.53 0.03 -0.73 0.33 0.03
EUS 1.48 1.01 0.14 0.06 0.53 0.91
FDG-PET 2.91 0.92 0.001 2.91 0.92 0.001
Coeff. coefficient, SE standard error, I one and first staging procedure, II second method/two staging procedures, III third method/three staging
procedures
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outcomes strongly overlap and strengthen each other.
FDG-PET reaches the highest LR? when CT is negative
(LR? = 12.5–13.0), and vice versa the LR? of CT
reaches 4.4. EUS is insensitive with respect to resectability,
with nonsignificant LRs when the results are expressed as a
dichotomous outcome. This finding is not in line with the
generally allotted role of EUS in esophageal cancer stag-
ing. One explanation might be that criteria based on nodal
status and depth of tumor invasion alone are not strong
enough to preclude surgical resection. Even though EUS is
a powerful test for detecting lymph node metastases and
tumor depth, these outcomes have almost no influence on
decision-making when incurability/irresectability is the
only parameter to be assessed. Only when EUS clearly
identifies patients with a T4b tumor or cytologically proven
nonregional nodes is it helpful for the exclusion of patients
from potentially curative surgery. In the current study, only
ten tumors (10/216; 5%) were considered as not curatively
resectable on EUS as they were staged as T4b tumors.
Usually the endoscopist will stage a tumor as T4 if he or
she is clearly convinced of tumor invasion into surrounding
structures precluding radical surgery. However, if invasion
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FIG. 2 Positive likelihood ratio of CT, FDG-PET, and EUS conditional on tumor length (a–c) and on histological type (d) stratified by negative
and positive test results of both other tests
and surgery
T2N+
T3N0/N+
Resectable T4N0/N+
T1-T2/N0
Primary chemoradiation:
and/or cisplatin-based
usually 50-60Gy/5FU
          
Palliation
Irresectable
FDG-PET/CT
Primary surgery Neoadj. treatment
Resectable Questionable
EUS-FNA EUS-FNA
EUS-FNA
FIG. 3 Flowchart illustrating optimal
staging protocol for patients with
esophageal cancer on split levels for
clearly resectable, questionably
resectable, and irresectable esophageal
tumors. 5FU 5-fluorouracil
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is not clear or is doubtful, the tumor will probably be
staged as T3 and the patient, in most cases, will be offered
neoadjuvant therapy as standard treatment. Based on these
results, EUS has limited impact beyond PET/CT on staging
advanced esophageal tumors in terms of curative resect-
ability. EUS seems to be more valuable as an additional
long-term prognostic factor rather than a potential predictor
of irresectability at time of diagnosis.
Currently, neoadjuvant chemoradiation is being increas-
ingly applied in the treatment of locally advanced esoph-
ageal cancer in an effort to improve microscopic radical
resectability and survival by downstaging the tumor pro-
cess and reducing local recurrence rates. In this way,
staging has major consequences on treatment selection and
also when comparing outcomes between studies and
institutes. Furthermore, EUS is an invasive diagnostic
procedure and not always applicable because of stenosis or
use of a less accurate miniprobe in up to 30% of cases,
which may lead to inadequate assessment of depth invasion
and nodal staging.20 Moreover, in a previous study the
perceived patient burden of EUS in assessment of the
preoperative tumor stage was relatively high compared
with CT and or PET/CT. Both EUS and FDG-PET
have relatively good accuracy in restaging esophageal
cancer after neoadjuvant therapy. Although both imaging
methods have their limitations in assessing response to
neoadjuvant chemoradiation, the accuracy rate of CT alone
is poor.21
The more tests used in a preoperative staging program,
the higher the chance of a correct outcome. However, one
must balance likelihoods and certitude against costs, radi-
ation, and inconvenience for the patient. Difficulties arise
when test outcomes are contradictory. This study offers a
new perspective on the performance of current diagnostic
tests in the staging workup for esophageal cancer patients.
It indicates the individual impact of each test on medical
decision-making and the congruence between them. These
results strongly argue for use of PET/CT as the first staging
procedure, reserving EUS-FNA for those cases with
uncertainty or disagreement about the location of positive
lymph nodes (regional versus nonregional nodes) or tumor
depth, which may affect curative resectability. Biopsies of
FDG-avid sites at time of EUS will actually increase the
yield of pathological proof from initial EUS without
scheduling a separate EUS to prove irresectable disease.
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